Literature DB >> 3682432

Immunohistochemical demonstration of estrogen, progesterone, CEA and ferritin in breast cancer and their clinical value for the prediction of early postoperative recurrence.

T Majima1, O Kojima, Y Uehara, H Tokuda, M Kano, T Takahashi.   

Abstract

The aim of this paper is to determine whether the incidence of estrogen-, progesterone-, CEA-, and ferritin- positive staining of primary tumors, by using the PAP method, is related to the prognosis of breast cancer status. A significantly higher incidence (71 per cent) of CEA-positive tumors was observed in patients who had a recurrence of breast cancer within 2 years after radical operation. Patients, whose tumors were positive in estrogen or negative in CEA, showed a relatively good prognosis, even after a recurrence of the disease. Distant metastases were seen in most of the patients positive in CEA (78 per cent). Before the recurrence of breast cancer, those patients positive in progesterone had a good prognosis. After the recurrence, however, there was no relationship between the prognosis of recurrent disease and the progesterone-staining of primary tumors. Our data suggest that the immunohistological staining of estrogen, progesterone and CEA might offer the effective prognostic indices in breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3682432     DOI: 10.1007/bf02470695

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  10 in total

1.  Specific progesterone receptors in human breast cancer.

Authors:  K B Horwitz; W L McGuire
Journal:  Steroids       Date:  1975-04       Impact factor: 2.668

2.  Clinical correlation between CEA and breast cancer.

Authors:  D C Tormey; T P Waalkes
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

3.  Correlation between carcinoembryonic antigen in gastric cancer tissue and survival of patients with gastric cancer.

Authors:  O Kojima; E Ikeda; Y Uehara; T Majima; Y Fujita; S Majima
Journal:  Gan       Date:  1984-03

4.  Histochemical assay of estrogen and progesterone receptors in breast cancer: correlation with biochemical assays and patients' response to endocrine therapies.

Authors:  L P Pertschuk; E H Tobin; E Gaetjens; A C Carter; G A Degenshein; N D Bloom; D J Brigati
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

5.  Estrogen receptor assay in primary breast cancer and early recurrence of the disease.

Authors:  P V Maynard; R W Blamey; C W Elston; J L Haybittle; K Griffiths
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

6.  Correlation of carcinoembryonic antigen in tissue sections with spread of mammary carcinoma.

Authors:  S Shousha; T Lyssiotis
Journal:  Histopathology       Date:  1978-11       Impact factor: 5.087

7.  Measurement of serum ferritin by radioimmunoassay: results in normal individuals and patients with breast cancer.

Authors:  D M Marcus; N Zinberg
Journal:  J Natl Cancer Inst       Date:  1975-10       Impact factor: 13.506

8.  PAP immunoperoxidase method demonstrating endogenous estrogen in breast carcinomas.

Authors:  M Shimizu; O Wajima; M Miura; I Katayama
Journal:  Cancer       Date:  1983-08-01       Impact factor: 6.860

9.  Comparative study of CEA staining in gastric and colorectal cancer tissues.

Authors:  O Kojima; T Tanioku; N Kitagawa; Y Uehara; T Majima; E Ikeda; N Iwai; Y Fujita; S Majima
Journal:  Gastroenterol Jpn       Date:  1984-02

10.  The clinical value of immunohistochemically demonstrable CEA in breast cancer: a possible method of selecting patients for adjuvant chemotherapy.

Authors:  S R Smith; A Howell; A Minawa; J M Morrison
Journal:  Br J Cancer       Date:  1982-11       Impact factor: 7.640

  10 in total
  1 in total

1.  Analysis of cytosol CA15-3, carcinoembryonic antigen, estrogen and progesterone receptors in breast cancer tissues.

Authors:  T Miya; T Watanabe; I Adachi; M Itabashi; T Fukutomi; K Yamaguchi; K Abe; M Arakawa
Journal:  Jpn J Cancer Res       Date:  1992-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.